| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/13/2006 | US20060078494 Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| 04/13/2006 | DE10394216T5 Hepatoprotektive pharmazeutische Zusammensetzung umfassend eine Mischung aus Coumarinlignoiden und Verfahren zur Herstellung derselben Hepatoprotective pharmaceutical composition comprising a mixture of coumarinolignoids and methods for making the same |
| 04/13/2006 | DE10328813B4 Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA-Sequenzen mittels triplexbildender Oligomere A method for the examination of cytosine methylations in DNA sequences by means triplexbildender oligomers |
| 04/13/2006 | DE102004052308A1 Octenidinhaltige Lutschtabletten gegen entzündliche Erkrankungen des Mund- und Rachenraums Octenidine lozenges against inflammatory diseases of the mouth and throat |
| 04/13/2006 | DE102004049291A1 Neue Oxadiazinon-Derivate und ihre Verwendung New Oxadiazinon derivatives and their use |
| 04/13/2006 | DE102004049078A1 Phenylpyrazole Phenylpyrazoles |
| 04/13/2006 | DE102004048877A1 New tricyclic thiazole derivatives useful as PI3 kinase inhibitors, for treating e.g. inflammatory and allergic airway and skin diseases, autoimmune and kidney disease |
| 04/13/2006 | DE102004047255A1 Prolinderivate Proline |
| 04/13/2006 | DE102004047254A1 Carbonylverbindungen Carbonyl compounds |
| 04/13/2006 | DE102004023635A1 Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate Heteroaryl-cyclohexyl-1,4-diamine derivatives |
| 04/13/2006 | DE10002304B4 Verwendung der 1,1-Dioxo-perhydro-1,2,4-thiadiazine Taurolidin oder Taurultam zur Behandlung von Neurodermitis Use of 1,1-dioxo-perhydro-1,2,4-thiadiazines taurolidine or taurultam for the treatment of atopic dermatitis |
| 04/13/2006 | CA2791783A1 Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel |
| 04/13/2006 | CA2583768A1 Agent for prophylaxis or treatment of metabolic syndrome |
| 04/13/2006 | CA2583472A1 Hcv ns3-ns4a protease inhibition |
| 04/13/2006 | CA2583431A1 Variant amyloid protein |
| 04/13/2006 | CA2583351A1 Combination anti-viral compositions comprising castanospermine and methods of use |
| 04/13/2006 | CA2583326A1 Receptor function regulating agent |
| 04/13/2006 | CA2583312A1 Process for the preparation of amorphous fluvastatin sodium |
| 04/13/2006 | CA2583287A1 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders |
| 04/13/2006 | CA2583149A1 Biomaterials consisting of sulphated hyaluronic acid and gellan to be used in the prevention of spinal adhesions |
| 04/13/2006 | CA2583079A1 Methods using glycosaminoglycans for the treatment of kidney disease |
| 04/13/2006 | CA2583073A1 A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction |
| 04/13/2006 | CA2582949A1 Liposomes with improved drug retention for treatment of cancer |
| 04/13/2006 | CA2582911A1 Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| 04/13/2006 | CA2582908A1 Macrocyclic sh2 domain binding inhibitors |
| 04/13/2006 | CA2582760A1 Modulators of hcv replication |
| 04/13/2006 | CA2582752A1 Fluorophosphonocinnamic compounds, synthesis and uses for treating disorders caused by oxidative stress |
| 04/13/2006 | CA2582615A1 Pharmaceutical composition for treatment of tear and salivary fluid drying |
| 04/13/2006 | CA2582482A1 Triazolopyridine derivatives as antibacterial agents |
| 04/13/2006 | CA2582449A1 Amorphous atorvastatin calcium |
| 04/13/2006 | CA2582405A1 Pharmaceutical compositions comprising fenofibrate and atorvastatin |
| 04/13/2006 | CA2582403A1 Pharmaceutical compositions comprising fenofibrate and atorvastatin |
| 04/13/2006 | CA2582356A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| 04/13/2006 | CA2582347A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| 04/13/2006 | CA2582346A1 Morphine and morphine precursors |
| 04/13/2006 | CA2582327A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | CA2582324A1 Compositions and methods for treating ophthalmic diseases |
| 04/13/2006 | CA2582300A1 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient |
| 04/13/2006 | CA2582299A1 Oral pharmaceutical preparation for proton pump antagonists |
| 04/13/2006 | CA2582294A1 Condensed tricyclic benzimidazoles for the treatment of gastrointestinal disorders |
| 04/13/2006 | CA2582289A1 Inhibition of tumour cell migration |
| 04/13/2006 | CA2582273A1 Compositions and methods for treating cognitive disorders using serotonin receptor antagonists |
| 04/13/2006 | CA2582256A1 Substituted tricyclic benzimidazoles |
| 04/13/2006 | CA2582045A1 Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy |
| 04/13/2006 | CA2581921A1 Benzoxazine and quinoxaline derivatives and uses |
| 04/13/2006 | CA2581651A1 Cholesterol-labelled modified rna |
| 04/13/2006 | CA2581638A1 Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| 04/13/2006 | CA2581596A1 Combinations of substituted azetidonones and cb1 antagonists |
| 04/13/2006 | CA2581489A1 Use of compounds for the prevention of drug-induced cell toxicity |
| 04/13/2006 | CA2581372A1 Treatment method |
| 04/13/2006 | CA2581282A1 Solid pharmaceutical preparation |
| 04/13/2006 | CA2581169A1 Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| 04/13/2006 | CA2581057A1 New piperidine antibiotics |
| 04/13/2006 | CA2581051A1 Pulmonary administration of an antithrombotic compound |
| 04/13/2006 | CA2580831A1 Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors |
| 04/13/2006 | CA2580525A1 Lercanidipine capsules |
| 04/13/2006 | CA2580221A1 Novel cyclic and acyclic propenones for treating cns disorders |
| 04/13/2006 | CA2577219A1 Use of caryophyllenes in the manufacture of medicaments and treatment of bodily conditions of inflammation and inflammatory pain |
| 04/13/2006 | CA2574500A1 D-pyranosyl-substituted phenyls, medicaments containing said compounds, use thereof, and method for the production thereof |
| 04/13/2006 | CA2562151A1 Oligonucleotides comprising a c5-modified pyrimidine |
| 04/13/2006 | CA2561993A1 Compositions and methods for modulating gated ion channels |
| 04/12/2006 | EP1646131A1 Dc motor |
| 04/12/2006 | EP1645634A2 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/12/2006 | EP1645558A1 Piperazinylpyrazines as serotonin 5-HT2C receptor modulators |
| 04/12/2006 | EP1645557A1 Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
| 04/12/2006 | EP1645556A1 Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents |
| 04/12/2006 | EP1645288A1 New nuclear transcription factors regulators |
| 04/12/2006 | EP1645287A2 Anhydrous topical skin preparations |
| 04/12/2006 | EP1645286A1 Drug for nerve regeneration |
| 04/12/2006 | EP1645281A1 Tripterygium wilfordii Hook F root preparation for birth control |
| 04/12/2006 | EP1645279A1 Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections |
| 04/12/2006 | EP1645278A2 Use of aliphatic polyamines for reducing oxalate |
| 04/12/2006 | EP1645277A1 Stable tetrodotoxin freeze drying medicinal preparation |
| 04/12/2006 | EP1645276A1 Treatment of neurodegenerative disorders |
| 04/12/2006 | EP1645275A1 Small organic molecule regulators of cell proliferation |
| 04/12/2006 | EP1645274A1 Process for making gatifloxacin form omega |
| 04/12/2006 | EP1645273A2 Novel use of (R)-(-)-2-(5-(-flourophenyl)-3-pyridylmethylaminoethyl|-chromane and its physiologically acceptable salts |
| 04/12/2006 | EP1645272A2 Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse |
| 04/12/2006 | EP1645271A1 Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| 04/12/2006 | EP1645270A2 Control of pain with endogenous cannabinoids |
| 04/12/2006 | EP1645267A2 Method for producing an active ingredient concentrate and active ingredient concentrate |
| 04/12/2006 | EP1645266A1 Aqueous suspension for nasal drops |
| 04/12/2006 | EP1644490A2 Transgenic cells |
| 04/12/2006 | EP1644482A1 Novel galactooligosaccharide composition and the preparation thereof |
| 04/12/2006 | EP1644394A2 Synthesis and compositions of 2 -terminator nucleotides |
| 04/12/2006 | EP1644392A1 Rapamycin carbohydrate derivatives |
| 04/12/2006 | EP1644376A1 PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS |
| 04/12/2006 | EP1644372A2 Substituted quinolin-4-ylamine analogues |
| 04/12/2006 | EP1644370A2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 04/12/2006 | EP1644369A2 Arylamine-substituted quinazolinone compounds |
| 04/12/2006 | EP1644367A1 Immunosuppressant compounds and compositions |
| 04/12/2006 | EP1644364A1 Tetrazol benzofurancarboxamides with pi3k activity as therapeutic agents |
| 04/12/2006 | EP1644358A2 Biaryl piperazinyl-pyridine analogues |
| 04/12/2006 | EP1644357A1 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 04/12/2006 | EP1644351A1 Imidazole derivatives iii |
| 04/12/2006 | EP1644349A1 Pharmaceutical compositions comprising cabbinochreme type compounds |
| 04/12/2006 | EP1644343A1 5-substituted quinazolinone derivatives |
| 04/12/2006 | EP1644338A1 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases |
| 04/12/2006 | EP1644337A1 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 04/12/2006 | EP1644336A1 Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin |